January 30, 2015 — The New England Journal of Medicine has published a report linking Aczone, a popular acne gel, with a rare blood disorder known as methemoglobinemia.
Aczone is a topical gel that contains 5% dapsone, an antibiotic that has been on the market for decades. Dapsone is well-known to increase the risk of methemoglobinemia, but this report is the first-known case linked to Aczone.
The case report involves a 19 year-old woman who visited the emergency room with blue lips and fingers, mild headache, and shortness of breath. She had been using a “pea-sized” amount of Aczone for the last seven days, but failed to tell her doctors.
After going through a number of tests, doctors detected dapsone in her urine and diagnosed her with methemoglobinemia.
Methemoglobinemia is a rare but serious blood disorder that can be inherited or acquired as a side effect of certain medications. It causes abnormal levels of the protein methemoglobin, which carries oxygen but is unable to deliver it effectively to body tissues.
Methemoglobinemia symptoms may include:
- Bluish coloring of the skin
- Shortness of breath
- Lack of energy
Do I have an Aczone Lawsuit?
The Schmidt Firm, PLLC is currently investigating Aczone induced injury cases in all 50 states. If you or somebody you know has been diagnosed with methemoglobinemia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.